GLP1R and chronic kidney disease: FIDELIO-DKD and FIGARO-DKD had a primary and secondary endpoint but were inverted (renal and cardiovascular endpoint, cardiovascular and renal endpoint, respectively, but with less pronounced CKD in the latter trial) [10,11]; the use of finerenone alone and in association with glucagon-like peptide-1 receptor agonists (GLP-1Ras) or sodium–glucose cotransporter two inhibitors (SGLT2is) has been shown to have cardiovascular benefits [12].